Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upSibylle Loibl, Nadia Harbeck, Fabrice André et al.|Annals of Oncology|2023Cited by 830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Joseph Gligorov et al.|Annals of Oncology|2021Cited by 724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast CancerEva Thomas, Miguel Martín, Josep Tabernero et al.|Journal of Clinical Oncology|2007Cited by 290
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical ImplicationsMaria Vittoria Dieci, Valentina Guarneri, Federica Miglietta|Cells|2021Cited by 227
Evolution of HER2-low expression from primary to recurrent breast cancerFederica Miglietta, Maria Vittoria Dieci, Gaia Griguolo et al.|npj Breast Cancer|2021Cited by 226